Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Passage BioPASG +2.00%30 Net Cash per Share is $1.07 as of Jun. 2026, which is 12% below its 10-year median of 1.22. GuruFocus rates PASG with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 796 Biotechnology companies, Passage Bio ranks better than 57.16% on this metric.
Passage Bio (NAS:PASG) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Passage Bio Net Cash per Share Related Terms
Passage Bio Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Passage Bio's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PASG vs OTLC, KTTA, LSTA: Net Cash per Share Comparison
For the Biotechnology subindustry, Passage Bio's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Passage Bio Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Passage Bio's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Passage Bio's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Passage Bio's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Passage Bio (PASG) has a Net Cash per Share of $1.07 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Passage Bio and its competitors. This is 12% below median its historical median of 1.22. Over the past decade, Passage Bio's Net Cash per Share has ranged from 0.40 to 13.56. According to the industry distribution chart, Passage Bio ranks #341 out of 796 companies in the Biotechnology industry, placing it in the top 42.8%.
Is Passage Bio's Net Cash per Share too high?
Passage Bio's current Net Cash per Share of $1.07 is 12% below median its 10-year median of 1.22. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 13.56. The Biotechnology industry median Net Cash per Share is 5.12. Passage Bio's value of $1.07 is 79.1% below this industry median. Based on the distribution chart, Passage Bio ranks #341 out of 796 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Passage Bio has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Passage Bio's Net Cash per Share compare to OTLC and KTTA?
According to the Biotechnology industry distribution chart, Passage Bio ranks #341 out of 796 companies for Net Cash per Share. This puts Passage Bio in the upper half of its industry. The industry median Net Cash per Share is 5.12. Passage Bio's value of $1.07 is 79.1% below this benchmark. Historically, Passage Bio's own Net Cash per Share has ranged from 0.40 to 13.56 over the past decade. While the company's 10-year median is 1.22 vs. the industry median of 5.12, Passage Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.12, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Passage Bio's current Net Cash per Share of $1.07 is 79.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Passage Bio and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Passage Bio's current Net Cash per Share is $1.07, which is 12% below median its own 10-year median of 1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Passage Bio stock overvalued right now?
Passage Bio (PASG) has a current Net Cash per Share of $1.07. The current Net Cash per Share is $1.07, which is 12% below median its 10-year median of 1.22 and 79.1% below the Biotechnology industry median of 5.12. Passage Bio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Passage Bio (PASG), the current Net Cash per Share is $1.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
30GF Score
Get the complete analysis for PASG
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PASG has been successfully added to your 
